Target Healthcare REIT (LON:THRL) Reaches New 1-Year High - Here's What Happened

Key Points

• Target Healthcare REIT reached a new 52-week high, trading as high as GBX 117 before closing at GBX 113, up 0.4%.
• The REIT reported its strongest annual performance since its 2013 IPO, including a 12.0% total accounting return, a 6.4% increase in net tangible assets and approximately £72.1 million in full-year revenue.
• The dividend was increased after earnings growth, supporting the stock’s income appeal; however, Jefferies maintained a “Hold” rating with a GBX 101 price target, below the current share price.

Target Healthcare REIT (LON:THRL - Get Free Report)'s share price reached a new 52-week high during trading on Thursday . The company traded as high as GBX 117 and last traded at GBX 113, with a volume of 94144 shares. The stock had previously closed at GBX 113.

Target Healthcare REIT News Roundup

Here are the key news stories impacting Target Healthcare REIT this week:

• Positive Sentiment: Dividend increased: Target Healthcare REIT raised its dividend following higher full-year earnings, reinforcing the stock’s income appeal. The company also provided quarterly dividend guidance for the year ending June 2027. Target Healthcare REIT raises dividend as full-year earnings grow
• Positive Sentiment: Record annual performance: The REIT reported its strongest annual performance since its 2013 initial public offering, including a 12.0% total accounting return and a 6.4% increase in net tangible assets. Target Healthcare REIT posts record returns and strengthens care home portfolio
• Positive Sentiment: Higher income and portfolio strengthening: Full-year revenue reached approximately £72.1 million, while management said it had strengthened the care-home portfolio. Reported quarterly EPS was GBX 13.32, with a 114.60% net margin and 11.03% return on equity. Target Healthcare REIT Plc Reveals Climb In Full Year Income
• Positive Sentiment: Insider-linked buying: The company disclosed a share purchase involving a closely associated person, which may provide a modest confidence signal regarding the investment outlook. Insider-Linked Share Purchase Disclosed at Target Healthcare REIT
• Neutral Sentiment: Target Healthcare REIT scheduled a live online presentation of its full-year results, giving investors an opportunity to assess occupancy, rent collection, funding costs and growth plans in greater detail. Target Healthcare REIT schedules live online full-year results presentation

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group reiterated a "hold" rating and issued a GBX 101 price objective on shares of Target Healthcare REIT in a report on Wednesday, August 5th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Target Healthcare REIT presently has a consensus rating of "Hold" and a consensus price target of GBX 101.

Target Healthcare REIT Stock Up 0.4%

The company has a market cap of £703.35 million, a PE ratio of 9.02, a PEG ratio of 1.48 and a beta of 0.71. The company's fifty day moving average is GBX 112.24 and its 200-day moving average is GBX 107.81.

Target Healthcare REIT (LON:THRL - Get Free Report) last released its quarterly earnings results on Wednesday, September 23rd. The company reported GBX 13.32 earnings per share for the quarter. Target Healthcare REIT had a return on equity of 11.03% and a net margin of 114.60%. Equities research analysts expect that Target Healthcare REIT will post 6.2219101 EPS for the current fiscal year.

Target Healthcare REIT Company Profile

Our investment objective is to provide shareholders with an attractive level of income together with the potential for capital and income growth, from a portfolio of UK care homes, diversified by tenant, geography, and resident payment profile. We only invest in modern, purpose-built homes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.